Heparin is a highly sulfated complex polysaccharide with anticoagulant activity and is clinically the first-line drug for the prevention and treatment of thromboembolic diseases. Together with HS, heparin is an important endogenous regulator of multiple biological pathways. Stable isotope labeling has attracted widespread attention as an effective tool for understanding compound structures. As new approaches centered on stable isotope labeling continue to expand, synthetic methods for building stable isotope-labeled compounds must evolve together to keep pace.
Among the many stable isotopes, the unique properties of deuterium allow it to be used in a wide variety of applications. In the field of medicine, deuterium-labeled molecules that can exhibit unique pharmacokinetic (PK)/pharmacodynamic (PD) properties have attracted increasing attention.
To enable creative control of precise chemical modifications to facilitate the development of new heparin products and novel biochemical and pharmacological assays, BOC Sciences utilizes our DCL™ platform to achieve selective or perdeuterated heparin. We also have the ability to synthesize multiple milligrams of bioengineered heparin.
Fig. 1 Biosynthetic isotopic enrichment of chemoenzymatically prepared perdeuteroheparin.
Synthesis of perdeuteroheparosan precursor using E. coli: The E. coli strain was cultured in 2H2O with heavy glycerol as the sole carbon source to obtain perdeuteroheparosan precursor.
Preparation of heparin from microorganisms using two sequential chemical and enzymatic modifications: chemical de-N-acetylation of perdeuterated heparin with aqueous NaOH and N-sulfated with (CH3)3N•SO3 to generate heavy N- sulfoheparosan(NSH). This chemically derived intermediate was then simultaneously epimerized with recombinant E. coli-expressed glucuronyl-C5-epimerase (Homo sapiens, Glce) and 2OST-1 (Cricetulus griseus, Hs2st1), yielded perdeutero-2-O-sulfo-NSH.
We prepared heavy heparin disaccharides by enzymatic depolymerization of the non-anticoagulant perdeuterated heparin and precursors, which can be used as stable isotope-labeled internal standards for quantification of heparin/HS in biological samples.
We were able to detect and quantify changes in plasma isotope concentrations over time using LC-MS/MS to determine the in vivo half-lives of perdeuterated heparin and unlabeled bioengineered heparin. And the anticoagulant activity of the heparin mixture was quantified by anti-factor Xa activity assay.
FIg. 2 LC-MS analysis of heavy heparin and precursors.
Deuterated heparin and its deuterated biosynthetic intermediates prepared by BOC Sciences have a variety of uses, including but not limited to:
We are extending our deuterated technology to other types of glycosaminoglycans.
BOC Sciences has always regarded intellectual property as the most valuable asset of the company and its customers. We have signed non-disclosure agreements with customers and employees before the project starts, and provide synthetic route design and synthesis services in strict accordance with the terms of the non-disclosure agreement, striving to provide customers with target compounds in the shortest time possible.
BOC Sciences' DCL™ platform provides a deuterium strategy for both high-end custom markets and basic product needs. Our main business areas cover drug development, omics analysis, scientific research testing, and other markets, and strive to promote the development of biomedicine and scientific research.